Thermo Fisher ditches bid to acquire Qiagen as offer falls short
[MASSACHUSETTS] Thermo Fisher Scientific ended its agreement to purchase Qiagen after its tender offer for the Dutch health-care company fell short.
Only about 47 per cent of Qiagen shares were tendered, Thermo Fisher said in a statement Thursday, meaning the minimum threshold for acceptance of the proposed deal hadn't been met. Qiagen will pay Thermo Fisher a reimbursement of US$95 million, according to the statement.
Some shareholders had been seeking a higher price for Qiagen than the 43 euros (S$69.7) per share Thermo Fisher had offered. Davidson Kempner, a top investor in Qiagen, had said that a price between 48 euros and 52 euros a share was more appropriate and had urged others to reject Thermo Fisher's offer, which had been increased from an initial 39 euros.
BLOOMBERG
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Possible class action lawsuit against Cordlife by customers could take at least 2 years
Chinese tariffs could leave cognac makers with too much brandy
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share